ng-641
Gene therapyexperimental
Clinical trial activity
3 trials · 6 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Oct 1, 2019 (NCT04053283)
Timeline
2010s
- Jan 1, 2019
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Oncolytic virusOTHER
Oncolytic virus other
Chemistry & pharmacology
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL5095283 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05043714 | Phase 1 | Dec 1, 2021 | Akamis Bio, Bristol-Myers Squibb, University of Liverpool |
| NCT04830592 | Phase 1 | Nov 30, 2021 | PsiOxus Therapeutics Ltd, The Clatterbridge Cancer Centre |
| NCT04053283 | Phase 1 | Oct 1, 2019 | PsiOxus Therapeutics Ltd, Washington University in St. Louis |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (6)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| PsiOxus Therapeutics Ltd | For profit | 2 | 2 | 1 | 2019 |
| Akamis Bio | For profit | 1 | 1 | 1 | 2021 |
| Bristol-Myers Squibb | For profit | 1 | 0 | 1 | 2021 |
| The Clatterbridge Cancer Centre | Academic/Hospital | 1 | 0 | 1 | 2021 |
| University of Liverpool | Academic/Hospital | 1 | 0 | 1 | 2021 |
| Washington University in St. Louis | Academic/Hospital | 1 | 0 | 1 | 2019 |
6 organizations
Page 1 / 1